1. Home
  2. PHVS vs UTL Comparison

PHVS vs UTL Comparison

Compare PHVS & UTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHVS
  • UTL
  • Stock Information
  • Founded
  • PHVS 2015
  • UTL 1984
  • Country
  • PHVS Netherlands
  • UTL United States
  • Employees
  • PHVS N/A
  • UTL N/A
  • Industry
  • PHVS Biotechnology: Pharmaceutical Preparations
  • UTL Power Generation
  • Sector
  • PHVS Health Care
  • UTL Utilities
  • Exchange
  • PHVS Nasdaq
  • UTL Nasdaq
  • Market Cap
  • PHVS 1.0B
  • UTL 922.5M
  • IPO Year
  • PHVS 2021
  • UTL N/A
  • Fundamental
  • Price
  • PHVS $18.86
  • UTL $53.94
  • Analyst Decision
  • PHVS Strong Buy
  • UTL
  • Analyst Count
  • PHVS 5
  • UTL 0
  • Target Price
  • PHVS $40.60
  • UTL N/A
  • AVG Volume (30 Days)
  • PHVS 73.1K
  • UTL 66.5K
  • Earning Date
  • PHVS 11-13-2024
  • UTL 02-11-2025
  • Dividend Yield
  • PHVS N/A
  • UTL 3.14%
  • EPS Growth
  • PHVS N/A
  • UTL 5.48
  • EPS
  • PHVS N/A
  • UTL 2.92
  • Revenue
  • PHVS N/A
  • UTL $496,900,000.00
  • Revenue This Year
  • PHVS N/A
  • UTL $0.73
  • Revenue Next Year
  • PHVS N/A
  • UTL $4.59
  • P/E Ratio
  • PHVS N/A
  • UTL $18.59
  • Revenue Growth
  • PHVS N/A
  • UTL N/A
  • 52 Week Low
  • PHVS $15.37
  • UTL $45.26
  • 52 Week High
  • PHVS $33.00
  • UTL $63.52
  • Technical
  • Relative Strength Index (RSI)
  • PHVS 51.83
  • UTL 38.20
  • Support Level
  • PHVS $18.18
  • UTL $53.15
  • Resistance Level
  • PHVS $19.88
  • UTL $55.14
  • Average True Range (ATR)
  • PHVS 1.11
  • UTL 1.14
  • MACD
  • PHVS 0.17
  • UTL -0.05
  • Stochastic Oscillator
  • PHVS 76.86
  • UTL 30.44

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

About UTL UNITIL Corporation

Unitil Corp is a holding company, through its subsidiaries it is engaged in the local distribution of electricity and natural gas throughout its service territories in the states of New Hampshire, Massachusetts, and Maine. It reports three segments namely utility gas operations, utility electric operations, and non-regulated.

Share on Social Networks: